LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Autonomous Microchannel Analyzer Combines with Smartphone for Off-Site Disease Diagnostics

By LabMedica International staff writers
Posted on 18 Feb 2020
Print article
Image: The photo shows a portable lab that plugs into a smartphone to diagnose diseases like malaria or coronavirus (Photo courtesy of Joseph Fuqua II, University of Cincinnati Creative Services)
Image: The photo shows a portable lab that plugs into a smartphone to diagnose diseases like malaria or coronavirus (Photo courtesy of Joseph Fuqua II, University of Cincinnati Creative Services)
A novel microchannel capillary flow assay platform for detection of pathogenic microorganisms or other antigens combines with a smartphone for display, data transfer, storage, and analysis.

Investigators at the University of Cincinnati (OH, USA) built the microchannel capillary flow assay (MCFA) platform to perform chemiluminescence based ELISA tests with lyophilized chemiluminescent reagents. The MCFA platform exploits the ultra-high sensitivity of chemiluminescent detection while eliminating the shortcomings associated with liquid reagent handling, control of assay sequence, and user intervention.

Functionally designed microchannels along with adequate hydrophilicity provided by the saliva sample produce a sequential flow of assay reagents, and the device autonomously performs the ultra-high sensitive chemiluminescence based ELISA. An attached smartphone for display, data transfer, storage and analysis, as well as the source of power, enabled the development of a point-of-care-testing (POCT) analyzer for disease diagnostics.

The current report described the use of the MCFA device for detection of the malaria biomarker PfHRP2. For this antigen a limit of detection (LOD) of eight nanograms per milliliter was achieved, which is sensitive enough to detect active malarial infection.

Furthermore, the investigators assert that the device can be adapted to diagnose other infectious diseases such as coronavirus, HIV or Lyme disease or innumerable other health conditions such as depression and anxiety.

"The performance is comparable to laboratory tests. The cost is cheaper. And it is user-friendly," said senior author Dr. Chong Ahn, distinguished university research professor at the University of Cincinnati. "We wanted to make it simple so anyone could use it without training or support. Right now it takes several hours or even days to diagnose in a lab, even when people are showing symptoms. The disease can spread."

The MCFA device was described in the January 27, 2020, online edition of the journal Microsystems & Nanoengineering.

Related Links:
University of Cincinnati

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.